||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Alliance Pharma Share Discussion Threads
Showing 1401 to 1424 of 1425 messages
|Sale of 12 M shares by Aviva - I'm hoping that's what's been holding the share price back. There are 472 M shares in issue and Aviva retain a 5% holding or ~23.6M shares. Means they've sold ~1/3 of their original holding, so quite significant.|
|This is going to pop soon - - north.|
|cumnor: Could be institutional swapses - i.e pre-arranged trades between houses off market.|
|TW nothing to do with 21ml volume whatsoever. Something up?|
|If TW tipped maybe best to wait a few weeks until short term punters sell to skim a small profit = prices fall back and then stop losses triggered - then maybe possible to consider - Apparently a well managed company though debt moderately high but being worked down. But DYOR etc.|
|21m traded??? A tad unusual|
|Tipped by TW again, which some regards as the Kiss of Death|
Thought the same thing, I think it's more the cash generation here that makes the level comfortable than the level itself.
Not a concern, but made me smile all the same.|
|this made me laugh -
"At the year-end, the adjusted net debt/EBITDA ratio was 2.8 times and comfortably below our banking covenant of 3.0 times."
COMFORTABLY - really??????????|
|Good buy rec in today's Times BUY|
|I agree. I think this is a bit under the radar, but definitely a long term hold|
|Guess the market is underwhelmed because of debt, gearing at 2.8. However it has reduced by £3m since June with the £5m Sinclair payment to come, so provided we can continue to keep cash rolling in and debt decreasing it's a bargain below 50p IMO.|
|Looks good, would have liked a bit more clarification on the compensation from Sinclair, but management seem capable and gains elsewhere in the business appear to be compensating for the issues with Kelo-stretch. In effect the £5 million and the US rights to Flammacerium could be considered a bonus in excess of expectations.
Happy to hold and may be tempted to add on any weakness in the new tax year.|
|Doubled up here|
|Excellent set of results and well done to the BOD. share price more than justified imo. Hopefully onwards and upwards.|
|Sales and profits have doubled nice|
|From April 2016:
"Since completion of the acquisition in mid-December 2015, sales of Kelo-stretchTM, which had been identified as a key growth brand, have been lower than anticipated despite extensive promotional activities by A. Menarini Asia-Pacific Pte. Ltd., our key partner in South East Asia. Despite this, other Sinclair brands they distribute for us are performing well. The relationship with Menarini remains strong and other opportunities are being positively explored. The 2016 impact of the Kelo-stretch shortfall is estimated at a possible reduction of £1.2m at the operating profit level. Notwithstanding this, trading to date for the Sinclair Healthcare Products in aggregate has remained in line with management's expectations."
"The fair value of intangible assets recognised on business combination comprise the following product related intangibles: Aloclair, Atopiclair, Flamma franchise, Kelo-cote, Kelo-stretch, Other Dermatology Products and Other Specialist Hospital Products."
Worth keeping an eye on amortisation of intangible assets at results.|
|Great news £5m better off this am|
|Buying ahead of results|
|I agree with your views re longer term prospects but suspect that as it grows it may become a target for a larger fish.|
|I have added on the recent weakness. Held since early 2011 and like the long term prospects and relative stability of the business. I intend for APH to remain in my portfolio for 10yrs +|
|Moderate volume and continuing fall in share price 4 day faller down 9.55% - No news. Could an II be unloading ? Looks as though going nowhere at the moment or could it be those who bought in on the Hardman reseach having stop losses triggered -
Any other thoughts / knowledge ?|